MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, advancing its efforts to commercialize voice-based impairment detection technology for workplace safety applications. The kiosks use artificial intelligence to analyze short voice samples for more than 140 acoustic markers associated with potential alcohol, drug or fatigue-related impairment, with models trained on more than 50 million data points. The prototypes are now entering testing, validation and data-analysis phases involving industry participants, speech specialists and software engineers as the company works to refine its predictive models and assess real-world performance.
MindBio is targeting safety-sensitive industries including mining, aviation, construction, transportation and law enforcement, where large workforces and operational risks can make conventional breath, saliva, urine and laboratory testing costly and time-consuming. The company’s approach is designed to provide rapid, scalable and less invasive initial screening, with individuals flagged for potential impairment able to undergo additional evaluation using established testing protocols. For more details, see the full article at https://ibn.fm/R2OqM.
MindBio Therapeutics is a biotechnology company that is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. For more information, visit the company’s website at www.MindBioTherapeutics.com.
The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF.
